Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML).

Annali dell'Istituto superiore di sanita - 1 Jan 2013

Cianfriglia Maurizio

Abstract excerpt

BACKGROUND: Monoclonal antibodies represent the fastest growing sector of pharmaceutical biotechnology and a number of antibody-based biopharmaceuticals have been approved for cancer treatment. However, in many cases the antibodies used for the treatment of tumors offer only a modest survival benefit to cancer patients. AIMS: In the present review-article we intend to analyze: i) the curative regimen gemtuzumab...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoglycosides
Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Cell Line, Tumor

Share to Immunochemistry

Share to Immunotoxins

Share to Leukemia, Myeloid, Acute

Source

Identifiers

PMID: 23771264
DOI: 10.4415/ANN_13_02_11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML).PMID 23771264Read ↗

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.Semantic proximity Read ↗

Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategiesSemantic proximity Read ↗

Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersSemantic proximity Read ↗

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLSemantic proximity Read ↗

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.Semantic proximity Read ↗

Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line.Semantic proximity Read ↗

Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.Semantic proximity Read ↗

The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives.Semantic proximity Read ↗

Drug resistance: still a daunting challenge to the successful treatment of AML.Semantic proximity Read ↗

Classical multidrug resistance in acute myeloid leukaemia.Semantic proximity Read ↗

Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.